DK2702172T3 - Fremgangsmåde til bestemmelse af klinisk relevant hypoxi ved cancer - Google Patents
Fremgangsmåde til bestemmelse af klinisk relevant hypoxi ved cancer Download PDFInfo
- Publication number
- DK2702172T3 DK2702172T3 DK12724283.2T DK12724283T DK2702172T3 DK 2702172 T3 DK2702172 T3 DK 2702172T3 DK 12724283 T DK12724283 T DK 12724283T DK 2702172 T3 DK2702172 T3 DK 2702172T3
- Authority
- DK
- Denmark
- Prior art keywords
- cancer
- clinically relevant
- determining clinically
- hypoxia
- relevant hypoxia
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/4925—Blood measuring blood gas content, e.g. O2, CO2, HCO3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Physics & Mathematics (AREA)
- Ecology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Radiology & Medical Imaging (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201170212 | 2011-04-29 | ||
PCT/DK2012/050144 WO2012146259A1 (en) | 2011-04-29 | 2012-04-30 | Method for determining clinically relevant hypoxia in cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2702172T3 true DK2702172T3 (da) | 2020-04-06 |
Family
ID=46178373
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12724283.2T DK2702172T3 (da) | 2011-04-29 | 2012-04-30 | Fremgangsmåde til bestemmelse af klinisk relevant hypoxi ved cancer |
Country Status (10)
Country | Link |
---|---|
US (1) | US10385399B2 (da) |
EP (1) | EP2702172B1 (da) |
JP (2) | JP6081447B2 (da) |
AU (2) | AU2012247868B2 (da) |
CA (1) | CA2834588A1 (da) |
DK (1) | DK2702172T3 (da) |
MX (1) | MX2013012648A (da) |
RU (1) | RU2013153096A (da) |
WO (1) | WO2012146259A1 (da) |
ZA (1) | ZA201308119B (da) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8703188B1 (en) | 2012-11-19 | 2014-04-22 | Azanta A/S | Dispersible tablet |
WO2019075320A1 (en) * | 2017-10-12 | 2019-04-18 | The Trustees Of Columbia University In The City Of New York | INCARN OF SLC2A1 AS BIOLOGICAL SUBSTANCE, TREATMENTS AND ASSOCIATED METHODS |
CN115252603A (zh) * | 2022-07-08 | 2022-11-01 | 深圳市第二人民医院(深圳市转化医学研究院) | indisulam在制备治疗膀胱癌的药物中的应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007314366A1 (en) | 2006-10-30 | 2008-05-08 | Southern Research Institute | Targeting NBS1-ATM interaction to sensitize cancer cells to radiotherapy and chemotherapy |
WO2008154927A1 (en) * | 2007-06-21 | 2008-12-24 | Genmab A/S | Novel methods for treating egfr-associated tumors |
JP2009011167A (ja) | 2007-06-29 | 2009-01-22 | Hiroshima Univ | 低酸素応答を制御する物質のスクリーニング方法及び低酸素応答を制御する医薬組成物 |
AU2009212401A1 (en) * | 2008-02-04 | 2009-08-13 | Bipar Sciences, Inc. | Methods of diagnosing and treating PARP-mediated diseases |
ES2325724B1 (es) | 2008-03-11 | 2010-05-31 | FUNDACION DE LA COMUNIDAD VALENCIANA "CENTRO DE INVESTIGACIONES PRINCIPE FELIPE" | Composicion farmaceutica para inhibir el factor de transcripcion inducible por hipoxia. moduladores de procesos patologicos de angiogenesis, oncogenesis, inflamacion, apoptosis y terapia celular. |
GB0922437D0 (en) * | 2009-12-22 | 2010-02-03 | Cancer Rec Tech Ltd | Hypoxia tumour markers |
US20140045915A1 (en) * | 2010-08-31 | 2014-02-13 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
-
2012
- 2012-04-30 DK DK12724283.2T patent/DK2702172T3/da active
- 2012-04-30 AU AU2012247868A patent/AU2012247868B2/en not_active Ceased
- 2012-04-30 JP JP2014506761A patent/JP6081447B2/ja not_active Expired - Fee Related
- 2012-04-30 EP EP12724283.2A patent/EP2702172B1/en active Active
- 2012-04-30 RU RU2013153096/10A patent/RU2013153096A/ru not_active Application Discontinuation
- 2012-04-30 MX MX2013012648A patent/MX2013012648A/es unknown
- 2012-04-30 CA CA2834588A patent/CA2834588A1/en not_active Abandoned
- 2012-04-30 WO PCT/DK2012/050144 patent/WO2012146259A1/en active Application Filing
- 2012-04-30 US US14/114,496 patent/US10385399B2/en active Active
-
2013
- 2013-10-30 ZA ZA2013/08119A patent/ZA201308119B/en unknown
-
2016
- 2016-10-04 AU AU2016238842A patent/AU2016238842B2/en not_active Ceased
- 2016-12-01 JP JP2016233904A patent/JP2017079750A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP2702172A1 (en) | 2014-03-05 |
AU2016238842B2 (en) | 2018-12-13 |
AU2016238842A1 (en) | 2016-10-27 |
JP6081447B2 (ja) | 2017-02-15 |
MX2013012648A (es) | 2014-05-27 |
US20150159218A1 (en) | 2015-06-11 |
AU2012247868A1 (en) | 2013-11-14 |
US10385399B2 (en) | 2019-08-20 |
ZA201308119B (en) | 2020-01-29 |
JP2014518616A (ja) | 2014-08-07 |
WO2012146259A1 (en) | 2012-11-01 |
JP2017079750A (ja) | 2017-05-18 |
RU2013153096A (ru) | 2015-06-10 |
EP2702172B1 (en) | 2020-01-01 |
AU2012247868B2 (en) | 2016-07-07 |
CA2834588A1 (en) | 2012-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2900061T3 (da) | Fremgangsmåde til forstærkning af specifikke immunterapier ved cancerbehandling | |
DK2761553T3 (da) | Betalingssystem | |
CO6811812A2 (es) | Anticuerpo anti-b7-h3 | |
CO7020871A2 (es) | Anticuerpos anti-il-36r | |
DK2776833T3 (da) | Cobinder-understøttet testfremgangsmåde | |
BR112014022692A2 (pt) | Molécula de ligação de antígeno multiespecífica | |
DK2751387T3 (da) | Selvsuspenderende proppanter til hydraulisk frakturering | |
BR112014007958A2 (pt) | método | |
CR20140127A (es) | Anticuerpo anti-abtcr | |
BR112014001237A2 (pt) | método | |
DK2732131T3 (da) | Positioneringsfremgangsmåde | |
BR112014001765A2 (pt) | método | |
DK2732260T3 (da) | Prøveopsamlingskit | |
DK2531526T3 (da) | Fremgangsmåde til opnåelse af antistoffer | |
BR112014009795A2 (pt) | método | |
EP2700030A4 (en) | DETERMINATION OF BORE INTEGRITY | |
DK2876447T3 (da) | Fremgangsmåde til detektering af cancer | |
FI20115703A0 (fi) | Näytteenotin | |
DK2726702T3 (da) | Brøndværktøj til bestemmelse af sideboringer | |
EP2758079A4 (en) | PROCESS WITH BIOMARKERS FOR LIVER DISEASE | |
BRDI7103909S (pt) | Perfil de bordeamento | |
EP2725342A4 (en) | CELL FOR OPTICAL ANALYSIS | |
DK2683371T3 (da) | Forbindelser og fremgangsmåder til forbedring af forringet endogen fibrinolyse ved anvendelse af histondeacetylasehæmmere | |
DK2474236T3 (da) | Fremgangsmåde til fremstilling af søde sager | |
FR2971421B1 (fr) | Composition biphase |